Last reviewed · How we verify
Tablet, Dispersible
At a glance
| Generic name | Tablet, Dispersible |
|---|---|
| Also known as | ACARIZAX 12 SQ-HDM, Standardised allergen extract from house dust mite |
| Sponsor | ALK-Abelló A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (PHASE2)
- Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease (PHASE2)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children (PHASE4)
- A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) (PHASE3)
- Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease (PHASE3)
- UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tablet, Dispersible CI brief — competitive landscape report
- Tablet, Dispersible updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI